Agonistic targeting of GITR enhances ex vivo human TIL functionality and may therefore be a promising approach for novel monotherapy or combined immunotherapies in primary pMRR CRC and CRLM. This evidence concerns the gene TNFRSF18 and colorectal carcinoma.